TY - JOUR T1 - Evaluation of the Immunogenicity of Oil-Based Mycoplasma gallisepticum Killed Vaccine in Broiler Chickens Experimentally Prepared from Local Isolate of Bangladesh AU - Rahman, Md. Masudur AU - Noor, Monira AU - Islam Basit, Md. Shamsul AU - Ahmed, Sultan AU - Mahbobur Rajib, Dewan Muhammad AU - Das, Shobhan JO - Journal of Animal and Veterinary Advances VL - 19 IS - 8 SP - 107 EP - 112 PY - 2020 DA - 2001/08/19 SN - 1680-5593 DO - javaa.2020.107.112 UR - https://makhillpublications.co/view-article.php?doi=javaa.2020.107.112 KW - CRD KW -Mycoplasma gallisepticum KW -PCR KW -serological evaluation KW -vaccine candidate AB - The study was aimed to evaluate the immunogenicity of experimentally prepared Mycoplasma gallisepticum killed vaccine in broiler chickens under field conditions in Bangladesh. Isolation and identification of Mycoplasma gallisepticum was performed by cultural, biochemical and PCR assays. Oil-based formalin killed mycoplasma vaccine was prepared from one field isolate. To evaluate the immunogenicity of the vaccine, day-old broiler chicks (n = 60) were randomly divided into three equal groups namely Group-A (non-vaccinated control), Group-B (trial vaccine) and Group-C (imported vaccine). Immunogenicity of locally prepared trial vaccine and imported vaccine was evaluated by ELISA. In chickens of control group (Group-A), the mean anti-MG ELISA antibody titer gradually decreased whereas that of trial vaccine (Group-B) and imported vaccine (Group-C) increased gradually after 15 days post-vaccination. The oil-adjuvant MG trial vaccine conferred anti-MG-ELISA antibodies in broilers after 15 days of vaccination that reached to the maximum level (2213.75±3.126) at 45 days post priming which is comparable with the imported vaccine (2121.75±3.431). The maternal antibody in chicks did not interfere with the trial and imported vaccines as both were killed vaccines. We conclude that the prepared vaccine candidate might be promising to control mycoplasmosis in Bangladesh. However, the protective efficacy of the vaccine needs to be evaluated before recommending the vaccine finally. ER -